Edity Therapeutics Overview
- Year Founded
-
2019
- Status
-
Private
- Employees
-
19
- Latest Deal Type
-
Early Stage VC
- Latest Deal Amount
-
$11.1M
- Investors
-
10
Edity Therapeutics General Information
Description
Operator of a biotechnology company intended to deliver protein therapeutics for patients. The company harnesses the immune system to deliver therapeutic proteins directly to the cytoplasm of target cells to reprogram cells and tissue back to health, enabling physicians to create an opportunity to change the course of the disease at the intracellular level via multiple mechanisms, including protein replacement, target modulation, genetic correction, and protein gain-of-function.
Contact Information
Website
www.edity-tx.comCorporate Office
- 10 Menachem Plaut Street
- Rehovot 7670609
- Israel
Corporate Office
- 10 Menachem Plaut Street
- Rehovot 7670609
- Israel
Edity Therapeutics Timeline
Edity Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 3. Early Stage VC | 29-Dec-2023 | $11.1M | Completed | Pre-Clinical Trials | ||
| 2. Equity Crowdfunding | 24-Oct-2023 | Completed | Pre-Clinical Trials | |||
| 1. Seed Round | 01-Sep-2021 | $2.28M | $2.28M | Completed | Pre-Clinical Trials |
Edity Therapeutics Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Preferred A-1 | ||||||||
| Preferred A-2 | ||||||||
| Preferred A | 5,000,000 | $0.010000 | $0.54 | $0.54 | 1x | $0.54 | 28.38% |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Opportunity Score
Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.
Exit Type
Evaluates the likelihood of a successful exit for investors, and the most likely exit type.
Edity Therapeutics Comparisons
Industry
Financing
Details
Edity Therapeutics Competitors (88)
One of Edity Therapeutics’s 88 competitors is Adverum Biotechnologies, a Formerly VC-backed company based in Redwood City, CA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Adverum Biotechnologies | Formerly VC-backed | Redwood City, CA | ||||
| Regenxbio | Formerly VC-backed | Rockville, MD | ||||
| TScan Therapeutics | Formerly VC-backed | Waltham, MA | ||||
| ERS Genomics | Corporate Backed or Acquired | Dublin, Ireland | ||||
| Selecta Biosciences | Formerly VC-backed | Watertown, MA |
Edity Therapeutics Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Edity Therapeutics Patents
Edity Therapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2026234677-A1 | Chimeric immune activation proteins and use thereof | Pending | 08-May-2025 | ||
| WO-2025253381-A1 | Cyclic gmp-amp synthase variants and use thereof | Pending | 04-Jun-2024 | ||
| EP-4084815-A1 | Delivery compositions and methods | Pending | 02-Jan-2020 | ||
| US-20230024904-A1 | Delivery compositions and methods | Pending | 02-Jan-2020 | ||
| WO-2021137241-A1 | Delivery compositions and methods | Inactive | 02-Jan-2020 | A61K35/17 |
Edity Therapeutics Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Edity Therapeutics Investors (10)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Dr. Reddy's | Corporation | Minority | ||
| Katao Venture Partners | Venture Capital | Minority | ||
| OurCrowd | Venture Capital | Minority | ||
| Gaingels | Venture Capital | Minority | ||
| Loop Ventures | Venture Capital | Minority |
Edity Therapeutics FAQs
-
When was Edity Therapeutics founded?
Edity Therapeutics was founded in 2019.
-
Where is Edity Therapeutics headquartered?
Edity Therapeutics is headquartered in Rehovot, Israel.
-
What is the size of Edity Therapeutics?
Edity Therapeutics has 19 total employees.
-
What industry is Edity Therapeutics in?
Edity Therapeutics’s primary industry is Biotechnology.
-
Is Edity Therapeutics a private or public company?
Edity Therapeutics is a Private company.
-
What is the current valuation of Edity Therapeutics?
The current valuation of Edity Therapeutics is .
-
What is Edity Therapeutics’s current revenue?
The current revenue for Edity Therapeutics is .
-
How much funding has Edity Therapeutics raised over time?
Edity Therapeutics has raised $13.6M.
-
Who are Edity Therapeutics’s investors?
Dr. Reddy's, Katao Venture Partners, OurCrowd, Gaingels, and Loop Ventures are 5 of 10 investors who have invested in Edity Therapeutics.
-
Who are Edity Therapeutics’s competitors?
Adverum Biotechnologies, Regenxbio, TScan Therapeutics, ERS Genomics, and Selecta Biosciences are some of the 88 competitors of Edity Therapeutics.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
